Business Context and Reporting Period
Company: Akebia Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 4, 2019
Context: The filing discloses a planned presentation at the Jefferies 2019 Healthcare Conference and provides an update on the Independent Data Monitoring Committee's review of the Company's clinical programs.
Key Financial Metrics
This Form 8-K is a disclosure of non-financial events and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
There are no financial material changes reported in this filing. The primary material event is the recommendation by the Independent Data Monitoring Committee in May 2019 regarding the Company's clinical trials.
Guidance, Outlook, and Management Commentary
- Clinical Update: The Independent Data Monitoring Committee recommended that the global Phase 3 PROTECT and INNOVATE programs for the product candidate vadadustat continue.
- Modifications: The Committee did not recommend any modifications to these programs.
- Investor Relations: Management planned to present this information at the Jefferies 2019 Healthcare Conference on June 4, 2019, and at subsequent investor and analyst meetings.
- Legal Disclaimer: The information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings.
Investor Verification Checklist
- Verify the full content of the presentation attached as Exhibit 99.1 for detailed clinical data.
- Review the Company's most recent 10-Q or 10-K for current financial position, cash runway, and burn rate, as this 8-K contains no financial data.
- Monitor future announcements regarding the progression of the vadadustat Phase 3 trials (PROTECT and INNOVATE).
- Confirm the Company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.